Clinical Features and Prognosis Analysis of Hormone Receptor-Positive, HER2-Negative Breast Cancer with Differential Expression Levels of Estrogen and Progesterone Receptors: A 10-Year Retrospective Study
Background. Estrogen and progesterone receptor status can predict breast cancer patient prognosis and treatment sensitivity, but research on low ER and PR levels and expression balance remains limited. Methods. From January 2010 to October 2016, 283 ER+/PR+/HER2-breast cancer patients who met the in...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | The Breast Journal |
| Online Access: | http://dx.doi.org/10.1155/2022/5469163 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552899864952832 |
|---|---|
| author | Jin Liu Mingyu Gan Zijing Lin Qin Deng Juan Deng Bin Zeng Yanling Shi Jia Ming |
| author_facet | Jin Liu Mingyu Gan Zijing Lin Qin Deng Juan Deng Bin Zeng Yanling Shi Jia Ming |
| author_sort | Jin Liu |
| collection | DOAJ |
| description | Background. Estrogen and progesterone receptor status can predict breast cancer patient prognosis and treatment sensitivity, but research on low ER and PR levels and expression balance remains limited. Methods. From January 2010 to October 2016, 283 ER+/PR+/HER2-breast cancer patients who met the inclusion criteria were enrolled and divided into the H group (ER > 10%, N = 261) and the L group (1% ≤ ER ≤ 10%, N = 22). Groups were further divided into the HH group (ER > 10%/PR > 20%, N = 201), the HL group (ER > 10%/ER 1% ≤ PR ≤ 20% PR, N = 60), the LH group (1% ≤ ER ≤ 10%/PR > 20%, N = 5), and the LL group (1% ≤ ER ≤ 10%/1% ≤ PR ≤ 20%, N = 17). The LH group was excluded due to its small size, leaving the clinical and prognostic characteristics of 2 large groups and 3 subgroups to be analyzed. Results. L group patients had significantly more stage N2 axillary lymph nodes than H group patients (31.8% vs. 9.2%, P = 0.007). Age (P = 0.011), menopause status (P = 0.001), and tumor size (P = 0.024) were significantly different in the HL vs. HH and LL groups. Five-year DFS (94.6% vs. 77.0%, P < 0.001) and 5-year OS (97.2% vs. 85.8%, P = 0.001) rates significantly differed between HH and HL. No significant differences in 5-year DFS (77.0% vs. 81.9%, P = 0.564) or 5-year OS (85.8% vs. 87.8%, P = 0.729) rates were observed between HL and LL; the OS rates of HL and LL were similar. Conclusion. In the group of ER+/PR+/HER2-patients, there was no significant prognostic difference between ER-low positive and ER-high positive groups, but low PR expression was significantly associated with a worse prognosis. The role of ER and PR balance in breast cancer progression and individualized treatment requires further investigation. |
| format | Article |
| id | doaj-art-23efc846d889494e9ce91e73069cfeb4 |
| institution | Kabale University |
| issn | 1524-4741 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Breast Journal |
| spelling | doaj-art-23efc846d889494e9ce91e73069cfeb42025-02-03T05:57:25ZengWileyThe Breast Journal1524-47412022-01-01202210.1155/2022/5469163Clinical Features and Prognosis Analysis of Hormone Receptor-Positive, HER2-Negative Breast Cancer with Differential Expression Levels of Estrogen and Progesterone Receptors: A 10-Year Retrospective StudyJin Liu0Mingyu Gan1Zijing Lin2Qin Deng3Juan Deng4Bin Zeng5Yanling Shi6Jia Ming7Department of Breast and Thyroid SurgeryDepartment of Biochemistry and Molecular BiologyDepartment of Breast and Thyroid SurgeryDepartment of Breast and Thyroid SurgeryDepartment of Breast and Thyroid SurgeryDepartment of Breast and Thyroid SurgeryDepartment of Breast and Thyroid SurgeryDepartment of Breast and Thyroid SurgeryBackground. Estrogen and progesterone receptor status can predict breast cancer patient prognosis and treatment sensitivity, but research on low ER and PR levels and expression balance remains limited. Methods. From January 2010 to October 2016, 283 ER+/PR+/HER2-breast cancer patients who met the inclusion criteria were enrolled and divided into the H group (ER > 10%, N = 261) and the L group (1% ≤ ER ≤ 10%, N = 22). Groups were further divided into the HH group (ER > 10%/PR > 20%, N = 201), the HL group (ER > 10%/ER 1% ≤ PR ≤ 20% PR, N = 60), the LH group (1% ≤ ER ≤ 10%/PR > 20%, N = 5), and the LL group (1% ≤ ER ≤ 10%/1% ≤ PR ≤ 20%, N = 17). The LH group was excluded due to its small size, leaving the clinical and prognostic characteristics of 2 large groups and 3 subgroups to be analyzed. Results. L group patients had significantly more stage N2 axillary lymph nodes than H group patients (31.8% vs. 9.2%, P = 0.007). Age (P = 0.011), menopause status (P = 0.001), and tumor size (P = 0.024) were significantly different in the HL vs. HH and LL groups. Five-year DFS (94.6% vs. 77.0%, P < 0.001) and 5-year OS (97.2% vs. 85.8%, P = 0.001) rates significantly differed between HH and HL. No significant differences in 5-year DFS (77.0% vs. 81.9%, P = 0.564) or 5-year OS (85.8% vs. 87.8%, P = 0.729) rates were observed between HL and LL; the OS rates of HL and LL were similar. Conclusion. In the group of ER+/PR+/HER2-patients, there was no significant prognostic difference between ER-low positive and ER-high positive groups, but low PR expression was significantly associated with a worse prognosis. The role of ER and PR balance in breast cancer progression and individualized treatment requires further investigation.http://dx.doi.org/10.1155/2022/5469163 |
| spellingShingle | Jin Liu Mingyu Gan Zijing Lin Qin Deng Juan Deng Bin Zeng Yanling Shi Jia Ming Clinical Features and Prognosis Analysis of Hormone Receptor-Positive, HER2-Negative Breast Cancer with Differential Expression Levels of Estrogen and Progesterone Receptors: A 10-Year Retrospective Study The Breast Journal |
| title | Clinical Features and Prognosis Analysis of Hormone Receptor-Positive, HER2-Negative Breast Cancer with Differential Expression Levels of Estrogen and Progesterone Receptors: A 10-Year Retrospective Study |
| title_full | Clinical Features and Prognosis Analysis of Hormone Receptor-Positive, HER2-Negative Breast Cancer with Differential Expression Levels of Estrogen and Progesterone Receptors: A 10-Year Retrospective Study |
| title_fullStr | Clinical Features and Prognosis Analysis of Hormone Receptor-Positive, HER2-Negative Breast Cancer with Differential Expression Levels of Estrogen and Progesterone Receptors: A 10-Year Retrospective Study |
| title_full_unstemmed | Clinical Features and Prognosis Analysis of Hormone Receptor-Positive, HER2-Negative Breast Cancer with Differential Expression Levels of Estrogen and Progesterone Receptors: A 10-Year Retrospective Study |
| title_short | Clinical Features and Prognosis Analysis of Hormone Receptor-Positive, HER2-Negative Breast Cancer with Differential Expression Levels of Estrogen and Progesterone Receptors: A 10-Year Retrospective Study |
| title_sort | clinical features and prognosis analysis of hormone receptor positive her2 negative breast cancer with differential expression levels of estrogen and progesterone receptors a 10 year retrospective study |
| url | http://dx.doi.org/10.1155/2022/5469163 |
| work_keys_str_mv | AT jinliu clinicalfeaturesandprognosisanalysisofhormonereceptorpositiveher2negativebreastcancerwithdifferentialexpressionlevelsofestrogenandprogesteronereceptorsa10yearretrospectivestudy AT mingyugan clinicalfeaturesandprognosisanalysisofhormonereceptorpositiveher2negativebreastcancerwithdifferentialexpressionlevelsofestrogenandprogesteronereceptorsa10yearretrospectivestudy AT zijinglin clinicalfeaturesandprognosisanalysisofhormonereceptorpositiveher2negativebreastcancerwithdifferentialexpressionlevelsofestrogenandprogesteronereceptorsa10yearretrospectivestudy AT qindeng clinicalfeaturesandprognosisanalysisofhormonereceptorpositiveher2negativebreastcancerwithdifferentialexpressionlevelsofestrogenandprogesteronereceptorsa10yearretrospectivestudy AT juandeng clinicalfeaturesandprognosisanalysisofhormonereceptorpositiveher2negativebreastcancerwithdifferentialexpressionlevelsofestrogenandprogesteronereceptorsa10yearretrospectivestudy AT binzeng clinicalfeaturesandprognosisanalysisofhormonereceptorpositiveher2negativebreastcancerwithdifferentialexpressionlevelsofestrogenandprogesteronereceptorsa10yearretrospectivestudy AT yanlingshi clinicalfeaturesandprognosisanalysisofhormonereceptorpositiveher2negativebreastcancerwithdifferentialexpressionlevelsofestrogenandprogesteronereceptorsa10yearretrospectivestudy AT jiaming clinicalfeaturesandprognosisanalysisofhormonereceptorpositiveher2negativebreastcancerwithdifferentialexpressionlevelsofestrogenandprogesteronereceptorsa10yearretrospectivestudy |